Objective: A new retrograde neuron-tracing technique with microspheres was used to explore the possible innervation of calcitonin gene-related peptide (CGRP)-immunolabeled vestibular afferent neurons in the vestibular efferent immunolabeled nucleus in the brainstem. Methods: 0.1 µl of 5% microfluorospheres was injected into the area of the vestibular efferent nucleus, which is located lateral to the genu of the facial nerve. CGRP immunohistochemistry was processed in serial sections of the brainstem at the facial nerve genu level. Double-labeled neurons with both CGRP immunoreactivity and microfluorospheres were examined with fluorescence and confocal laser microscopy. Results: Three types of labeled neurons were observed: (1) neurons only retrogradely microfluorosphere-labeled that were mainly located in the medial vestibular nucleus, lateral vestibular nucleus, superior vestibular nucleus and parvicellular reticular nucleus on the ipsilateral side of the injection; (2) neurons that were both immunolabeled with CGRP and also retrogradedly labeled with microfluorospheres, indicating that they are CGRP cells projecting to the area of vestibular efferent nucleus, these cells were mainly distributed in the superior vestibular nucleus and dorsal vestibular nucleus, and (3) cells only immunolabeled for CGRP that were scattered extensively in the brainstem. Conclusion: The presented methodical contribution demonstrates the suitability of fluorescein-labeled microspheres for retrograde neuronal tracing. The vestibular nuclei contain numerous afferent neurons that send projections to the vestibular efferent nucleus, some of which are CGRP cells. This afferent innervation provides morphological evidence that the vestibular efferent neurons receive input from the vestibular afferent neurons including CGRP cells. These vestibular primary CGRP afferent neurons may have an influence on vestibular efferent neurons. CGRP acts as an important co-transmitter or modulator in the afferent-mediated activity of vestibular efferent neurons, which in turn affect afferents in the vestibular end organs.

Keywords:
Retrograde neuron-tracing technique, Microspheres, Afferent neurons, vestibular, Efferent neurons, vestibular, Calcitonin gene-related peptide
1.
Katz LC, Burkhalter A, Dreyer WJ: Fluorescent latex microspheres as a retrograde neuronal marker for in vivo and in vitro studies of visual cortex. Nature 1984;310:498–500.
2.
Divac I, Mogensen J: Long-term retrograde labelling of neurons. Brain Res 1990;524:339–341.
3.
Peltier AC, Bishop GA: The site of origin of calcitonin gene-related peptide-like immunoreactive afferents to the inferior olivary complex of the mouse. Neurosci Res 1999;34:177–186.
4.
Perachio AA, Kevetter GA: Identification of vestibular efferent neurons in the gerbil: histochemical and retrograde labelling. Exp Brain Res 1989;78:315–326.
5.
Ryan AF, Simmons DM, Watts AG, Swanson LW: Enkephalin mRNA production by cochlear and vestibular efferent neurons in the gerbil brainstem. Exp Brain Res 1991;87:259–267.
6.
Boyle R, Highstein SM: Efferent vestibular system in the toadfish: action upon horizontal semicircular canal afferents. J Neurosci 1990;10:1570–1582.
7.
Boyle R, Carey JP, Highstein SM: Morphological correlates of response dynamics and efferent stimulation in horizontal semicircular canal afferents of the toadfish, Opsanus tau. J Neurophysiol 1991;66:1504–1521.
8.
Brichta AM, Goldberg JM: Afferent and efferent responses from morphological fiber classes in the turtle posterior crista. Ann NY Acad Sci 1996;781:183–195.
9.
Goldberg JM, Fernandez C: Efferent vestibular system in the squirrel monkey: anatomical location and influence on afferent activity. J Neurophysiol 1980;43:986–1025.
10.
Highstein SM: The central nervous system efferent control of the organs of balance and equilibrium. Neurosci Res 1991;12:13–30.
11.
McCue MP, Guinan JJ Jr: Influence of efferent stimulation on acoustically responsive vestibular afferents in the cat. J Neurosci 1994;14:6071–6083.
12.
Rossi ML, Martini M: Efferent control of posterior canal afferent receptor discharge in the frog labyrinth. Brain Res 1991;555:123–134.
13.
Blanks RH, Precht W: Functional characterization of primary vestibular afferents in the frog. Exp Brain Res 1976;25:369–390.
14.
Hartmann R, Klinke R: Efferent activity in the goldfish vestibular nerve and its influence on afferent activity. Pflugers Arch 1980;388:123–128.
15.
Precht W, Llinas R, Clarke M: Physiological responses of frog vestibular fibers to horizontal angular rotation. Exp Brain Res 1971;13:378–407.
16.
Marlinsky VV: The effect of somatosensory stimulation on second-order and efferent vestibular neurons in the decerebrate decerebellate guinea-pig. Neuroscience 1995;69:661–669.
17.
Plotnik M, Marlinski V, Goldberg JM: Reflections of efferent activity in rotational responses of chinchilla vestibular afferents. J Neurophysiol 2002;88:1234–1244.
18.
Caratsch CG, Eusebi F: Effect of calcitonin gene-related peptide on synaptic transmission at the neuromuscular junction of the frog. Neurosci Lett 1990;111:344–350.
19.
van Rossum D, Hanisch UK, Quirion R: Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997;21:649–678.
20.
Kong WJ, Scholtz AW, Kammen-Jolly K, Gluckert R, Hussl B, von Cauvenberg PB, Schrott-Fischer A: Ultrastructural evaluation of calcitonin gene-related peptide immunoreactivity in the human cochlea and vestibular endorgans. Eur J Neurosci 2002;15:487–497.
21.
Petko M, Santa A: Distribution of calcitonin gene-related peptide immunoreactivity in the central nervous system of the frog, Rana esculenta. Cell Tissue Res 1992;269:525–534.
22.
Inagaki S, Kito S, Kubota Y, et al: Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res 1986;374:287–298.
23.
Chi F, Wang Z, Li K: Calcitonin gene-related peptide changes in efferent vestibular system during vestibular compensation. Zhonghua Er Bi Yan Hou Ke Za Zhi 1999;34:11–13.
24.
Jiao Y, Chi FL: Connection of efferent neurons and afferent vestibular nuclei in rat. Zhonghua Er Bi Yan Hou Ke Za Zhi 2004;39:469–471.
25.
Chi FL, Jiao Y, Yuany S: Mutual interaction of vestibular afferent nervous system and vestibular efferent nervous system in vestibular compensation. Zhonghua Er Bi Yan Hou Ke Za Zhi 2005;40:111–114.
26.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 3. New York, Academic Press, 1997.
27.
Bishop GA: Calcitonin gene-related peptide modulates neuronal activity in the mammalian cerebellar cortex. Neuropeptides 1995;28:85–97.
28.
Wackym PA, Popper P, Ward PH, et al: Cell and molecular anatomy of nicotinic acetylcholine receptor subunits and calcitonin gene-related peptide in the rat vestibular system. Otolaryngol Head Neck Surg 1991;105:493–510.
29.
Mulderry PK, Ghatei MA, Bishop AE, et al: Distribution and chromatographic characterization of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept 1985;12:133–143.
30.
Ohno K, Takeda N, Yamano M, Matsunaga T, Tohyama M: Coexistence of acetylcholine and calcitonin gene-related peptide in the vestibular efferent neurons in the rat. Brain Res 1991;566:103–107.
31.
Dememes D, Broca C: Calcitonin gene-related peptide immunoreactivity in the rat efferent vestibular system during development. Brain Res Dev Brain Res 1998;108:59–67.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.